Core Viewpoint - The company Valiant Pharmaceuticals (维立志博-B, 09887) experienced a significant stock price fluctuation, initially dropping but later increasing by over 5% after the announcement of its core product, LBL-024, receiving orphan drug designation from the European Commission for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC) [1] Group 1: Product Development - LBL-024 has reached an important milestone in its global development process by obtaining orphan drug status, which provides various incentives including 10 years of market exclusivity and regulatory fee waivers [1] - The product has demonstrated first-in-class (FIC) or best-in-class (BIC) potential in Phase II or registration clinical trials for non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC [1] Group 2: Clinical Trials and Approvals - LBL-024 is an antibody that targets both PD-L1 and 4-1BB, showing promising efficacy signals in two clinical trials conducted in China [1] - The company is set to receive approval from the National Medical Products Administration (NMPA) in April 2024 to conduct a single-arm registration clinical trial, with breakthrough therapy designation for the treatment of advanced extra-pulmonary neuroendocrine carcinoma expected in October 2024 [1]
维立志博-B尾盘涨逾5% 双特异性抗体维利信获欧盟孤儿药认定